Annexuzlimab is under clinical development by MedAnnex and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Annexuzlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Annexuzlimab overview

Annexuzlimab is under development for the treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and solid tumors including triple-negative breast cancer, bile duct cancer (cholangiocarcinoma), bladder cancer, colorectal cancer, ovarian cancer, kidney cancer (renal cell cancer), liver cancer, metastatic pancreatic cancer, gastric cancer, prostate cancer, lung cancer. It is a humanized monoclonal antibody targeting annexin-1. It is administered by intravenous route.

MedAnnex overview

MedAnnex is a biotechnology company that provides monoclonal antibodies. The company provides development of new treatments for autoimmune diseases. It provides annexuzlimab, a specific monoclonal antibody used to treat complex autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus among others. Annexuzlimab targets annexin-1, which is over-expressed in patients suffering from autoimmune diseases. The company provides obstructing annexin-1 with annexuzlimab, in experimental models, led to the reversal of progression of many autoimmune diseases. It also provides non-clinical testing programs. MedAnnex is headquartered in Edinburgh, Scotland, the UK.

For a complete picture of Annexuzlimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.